

Oxidation of Ellipticine with *Fremy's* Salt under Sonochemical Conditions

Oxidation von Ellipticin mit "Fremy-Salz" unter Ultraschallbedingungen

Felix Pautet^{a)}*, Pascal Formisyn^{b)}, and Jacques Bourgois^{b)}

^{a)} Laboratoire de Chimie Organique, Institut des Sciences Pharmaceutiques et Biologiques, 8, avenue Rockefeller, F-69373 Lyon Cedex 08, France

^{b)} Laboratoire de Genie Industriel et Biotechnologie, Ecole des Mines de Saint-Etienne, 158 Cours Fauriel, F-42023 Saint-Etienne Cedex 2, France

Received March 19, 1993

Ellipticine (**E**) **1** is an indolic alkaloid with antitumor activity¹⁾. Some of its phenolic derivatives as *N*-methyl-9-hydroxyellipticine (celiptinium), obtained from 9-hydroxyellipticine (**9-OH E**), exhibit high cytotoxic activity²⁾. Syntheses of **9-OH E** from 5-methoxyindole via 9-methoxyellipticine are not satisfactory if one considers yields and cost.


An interesting alternative route was to use indole, a less expensive product compared to 9-methoxyindole, to obtain **E** as starting compound for the hydroxyl derivative.

Recently, a regioselective formylation of **E** followed by *Baeyer-Villiger* oxidation has been reported as an expedient synthesis of **9-OH E**³⁾. Before knowing this result, we tried to carry out the same conversion by direct oxidation of **1** as in the *in vivo* metabolism⁴⁾.

Results and discussion

In the present study we have found that ellipticine (**1**) is not oxidized to **9-OH E** by various P450 chemical models (metalloporphyrins activated by PhIO, NaOCl, mCPBA, H₂O₂, Bu₄NHSO₅; VO(acac)₂/PhIO₂; H₂O₂/Fe(III)/CH₃CN), whilst under the same conditions, **9-OH E** is easily transformed in 9-oxoellipticine (**9-OXO E**; **2**), in agreement with results obtained with the potassium hydrogenopersulfate-metalloporphyrin system⁵⁾.

So the potassium nitrosodisulfonate (*Fremy's* salt), a valuable oxidant for the synthesis of quinone-imines from heterocyclic amines^{6,7)}, was studied. Under these conditions the first chemical conversion of **E** (**1**) to **9-OXO E** (**2**) was observed, then its reduction into **9-OH E** was easily realized with ascorbic acid⁸⁾.



Scheme

The radical nature of *Fremy's* salt led us to carry out the oxidation reaction under ultrasonic conditions in order to promote single electron transfers and so increase the yields. Some of our results are reported in the Table. The sensitivity of the heterogeneous oxidation reaction with *Fremy's* salt to ultrasonic effects was confirmed. Under optimal con-

Table: Experimental conditions and yields of **9-OXO E**

Conditions ^{a)}	Solvent	Min	Yield (%) ^{b)}
Stirring	Benzene	75	20
Stirring	Chloroform	75	15
))))) ^{c)} , Bath	Benzene	30	20
)))))	Benzene	15	40
)))))	Chloroform	15	35
)))))	Benzene	15	35
)))))	Benzene	15	25
)))))	Chloroform	15	20
)))))	Benzene	15	10

^{a)} At 20°C.

^{b)} Calculated for isolated products.

^{c)}))))): Ultrasonic conditions.

ditions (probe 4 mm and intensity 40W) 40% of the expected quinone-imine **2** was obtained.

The reactions are very sensitive to the solvent used; with acetone, acetonitrile, and THF only traces of **9-OXO E** (**2**) were obtained. With the more energetic probe (18 mm, used at 100 W) the lowest yield was obtained. In this case unidentified products, resulting probably of dimerisation, were formed. This reaction appears to be of type 3 (true sonochemical reaction in heterogeneous medium) in the classification established by Luche⁹⁾.

In conclusion, *Fremy's* salt is actually the only chemical oxidant known to carry out the direct conversion of **E** (**1**) into **9-OXO E** (**2**).

We thank the Sanofi group for the gift of **E** (**1**) and **9-OH E**.

Experimental Part

Sonochemical reactions: Sonoclean S-1000 bath, Labsonic U generator (probes: 4 mm diameter, 0-50 W electrical power input; 9.5 mm, 0-45 W; 18 mm, 0-150 W). Reaction vessel: thermostated cylinder, 35 mm diameter, 80 mm depth. Column chromatography: Amicon silicagel Si60 (35-70 µm). Melting points: Büchi 510 (uncorr.). - IR spectra: Perkin-Elmer 1310. - ¹H-NMR spectra: Bruker AM 300 (300 Mz, TMS int. stand.).

Oxidation of ellipticine (**1**)

To a solution of **1** (0.2 mmol) in solvent (20 ml) was added slowly, with a syringe, a solution of *Fremy's* salt (0.4 mmol) in 1 ml of a KH₂PO₄ aqueous solution (0.16 mol/l) diluted in 6 ml of water. After sonication the mixture was extracted with CHCl₃ (2 x 30 ml). The org. phase was evaporated after drying and the residue was chromatographed (eluent: C₆H₆, CHCl₃, EtOH, 3/2/1) to give pure **9-OXO E** (**2**) as a red solid. - m.p.: 345°C. - IR (KBr): $\tilde{\nu}$ = 1600 cm⁻¹ (C=N); 1630 (C=O). - ¹H-NMR (CDCl₃): δ (ppm) = 9.39 (s; 1H, 1-H), 8.64 (d; J = 6 Hz, 1H, 3-H), 7.75 (d; J = 6, 1H, 4-H), 7.44 (d; J = 10, 1H, 7-H), 6.80 (s; 1H, 10-H), 6.51 (dd; J = 10 and 1, 1H, 8-H), 2.79 (s; 3H, 11-CH₃), 2.78 (s; 3H, 5-CH₃). - These data are in agreement with those already reported¹⁰⁾.

Reduction of 9-OXO-E (2)

To a solution of **2** (0.2 mmol) in ethanol (20 ml) were added under stirring 0.20 mmol of ascorbic acid. After disappearance of the red tint the solvent was evaporated and the residue was purified as above to give 9-OH **E** as a yellow solid. - Yield 95%; m.p. >330°C. - IR (KBr): $\tilde{\nu}$ = 3400 cm⁻¹ (OH); 3100 (NH). - ¹H-NMR ([D₆]DMSO): δ (ppm) = 11.06 (s; 1H, OH), 9.65 (s; 1H, 1-H), 9.10 (s; 1H, NH), 8.41 (d; J = 6 Hz, 1H, 3-H), 7.89 (d; J = 6, 1H, 4-H), 7.77 (s; 1H, 10-H), 7.38 (d; J = 8.6, 1H, 7-H), 7.02 (d; J = 8.6, 1H, 8-H), 3.20 (s; 1H, 11-CH₃), 2.70 (s; 3H, 5-CH₃). - These data are identical to that of an authentic sample.

References

- 1 G.H. Svoboda, G.A. Poore, M.L. Monfort, *J. Pharm. Sci.* **1968**, 57, 1720-1725.
- 2 B. Dugue, C. Auclair, B. Meunier, *Cancer Res.* **1986**, 46, 3828-3833.
- 3 J.P.M. Plug, G.J. Koomen, U.K. Pandit, *Synthesis* **1992**, 1221-1222.
- 4 C. Paoletti, P. Leconte, P. Lesca, S. Cros, N. Dat-Xuong, D. Mansuy, *Biochimie*, **1978**, 60, 1003-1009.
- 5 J. Bernadou, M. Bonnafous, G. Labat, P. Loiseau, B. Menunier, *Drug Metab. Disp.* **1991**, 19, 360-365; Chem. Abstr. **1991**, 114, 220708.
- 6 A. Ziminer, D.C. Lankin, S.W. Horgan, *Chem. Rev.* **1971**, 71, 229-246.
- 7 Y. Ueno, *Pharmazie* **1986**, 41, 511.
- 8 P. Formisyn, F. Pautet, J. Bourgois, *J. Pharm. Biomed. Anal.* **1992**, 10, 427-436.
- 9 J.L. Luche, C. Einhorn, J. Einhorn, J.V. Sinistera, *Tetrahedron Lett.* **1990**, 31, 4125-4128.
- 10 C. Auclair, C. Paoletti, *J. Med. Chem.* **1981**, 24, 289-295.

[KPh598]

© VCH Verlagsgesellschaft mbH, D-69451 Weinheim, 1993 – Printed in the Federal Republic of Germany

Verantwortlich für die Redaktion: Prof. Dr. W. Wiegrebe, Pharmazeutisches Institut der Universität Regensburg, Universitätsstraße 31, Postfach 397, D-93053 Regensburg. – Anzeigenleitung: R.J. Roth, D-69451 Weinheim – VCH Verlagsgesellschaft mbH (Geschäftsführer: Hans Dirk Köhler, Dr. Karlheinz Köpfer), Postfach 101161, D-69451 Weinheim – Alle Rechte, insbesondere die der Übersetzung in fremde Sprachen, vorbehalten. Kein Teil dieser Zeitschrift darf ohne schriftliche Genehmigung des Verlages in irgendeiner Form – durch Photokopie, Mikrofilm oder irgendein anderes Verfahren – reproduziert oder in eine von Maschinen, insbesondere von Datenverarbeitungsmaschinen verwendbare Sprache übertragen oder übersetzt werden. – All rights reserved (including those of translation into foreign languages). No part of this issue may be reproduced in any form – photoprint, microfilm, or any other means – nor transmitted or translated into a machine language without the permission in writing of the publishers. – Von einzelnen Beiträgen oder Teilen von ihnen dürfen nur einzelne Vervielfältigungsstücke für den persönlichen und sonstigen eigenen Gebrauch hergestellt werden. Die Weitergabe von Vervielfältigungen, gleichgültig zu welchem Zweck sie hergestellt werden, ist eine Urheberrechtsverletzung. Der Inhalt dieses Heftes wurde sorgfältig erarbeitet. Dennoch übernehmen Autoren, Herausgeber, Redaktion und Verlag für die Richtigkeit von Angaben, Hinweisen und Ratschlägen sowie für eventuelle Druckfehler keine Haftung. This journal was carefully produced in all its parts. Nevertheless, authors, editors and publishers do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. – Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen u. dgl. in dieser Zeitschrift berechtigt nicht zu der Annahme, daß solche Namen ohne weiteres von jedermann benutzt werden dürfen. Es handelt sich häufig um gesetzlich eingetragene Warenzeichen, auch wenn sie in dieser Zeitschrift nicht als solche gekennzeichnet sind. Textfassung und EDV-Bearbeitung: Fa. Hellinger, D-69253 Heilighausen; Druck und Buchbinder: Rheinheissische Druckwerkstätte, D-55232 Alzey. – Unverlangt zur Rezension eingehende Bücher werden nicht zurückgeschickt.

Valid for users in the USA: The appearance of the code at the bottom of the first page of an article in this journal (serial) indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that copier pay the stated percopy fee through the Copyright Clearance Center, Inc., for copying beyond that permitted by Sections 107 for 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective work, or for resale. For copying from back volumes of this journal see »Permissions to Photo-Copy: Publisher's Fee List« of the CCC.

Printed on chlorine- and acid-free paper/Gedruckt auf säurefreiem und chlorfrei gebleichtem Papier